PPAR{gamma} Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model

Conclusion: These results suggest that combining PIO along with CDDP could be an effective treatment strategy for osteosarcoma and has important clinical potential for patients.

Source: Cancer Genomics and Proteomics - December 26, 2019 Category: Cancer & Oncology Authors: HIGUCHI, T., YAMAMOTO, J., SUGISAWA, N., TASHIRO, Y., NISHINO, H., YAMAMOTO, N., HAYASHI, K., KIMURA, H., MIWA, S., IGARASHI, K., BOUVET, M., SINGH, S. R., TSUCHIYA, H., HOFFMAN, R. M. Tags: Article Source Type: research